The bottom line: outcomes after conservation treatment in XXXX .

@entity1 @entity137 @entity5 @entity1138 @entity957 @entity79 @entity1398 @entity204 @entity1487
At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 @entity1 with @entity957 of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed @entity1138 and @entity1487 ). Five-year overall survival was 64% (95% confidence interval (CI): 48-79%), with a median survival of 9.75 years (median follow up 5.6 years, range 5 months to 22.5 years). Ten @entity1 have died of disease. At 2 years the local control rate was 86%, and colostomy-free survival was 83%. Relapse after 2 years was uncommon. @entity5 size was the main factor driving outcomes, especially survival. @entity1 with @entity5 (T > 4 cm) had a hazard ratio for survival of 5.7 (95% CI: 1.8-17). Fourteen (24%) @entity1 experienced treatment interruptions as a result of acute @entity137 , including one @entity204 from @entity1398 . Seven (12%) @entity1 , in total, experienced one or more late toxicities, grade 3 or above, including four @entity1 (all postmenopausal) who developed a radiation-induced @entity79 . Most @entity1 with @entity5 can expect to retain a functional sphincter after chemoradiation/radiation. Further studies are in progress to determine the optimal chemoradiation protocol.
